NITI Aayog member (health) Dr VK Paul said that the Covaxine has been approved for Phase II / III clinical trials in people between 2 to 18 years of age by Drugs Controller General India (DCGI). This trial will begin in the next 10 to 12 days.
COVAXIN has been approved by the Drugs Controller General of India (DCGI), for Phase II/III clinical trials in the age group of 2 to 18 years. I have been told that trials will begin in the next 10-12 days: Dr. VK Paul, Member-Health, Niti Aayog #COVID19 pic.twitter.com/T0ITsJsixA
– ANI (@ANI) May 18, 2021
On DRDO-developed anti-covid drug 2DG, he told that he would test the drug in the COVID-19 National Task Force, which would decide to include it in the treatment protocol. The Drugs Controller General of India (DCGI) has approved it in emergency use.
What did the government say on variants found in Singapore?
At the same time, on the variants found in Singapore, Dr. VK Paul said that they are testing the report of that particular variant. He said that in case of COVID-19 among children, it is reassuring that they do not get serious infection. They are watching it.
CBSE 10th result will be delayed, the board has extended the deadline to send the mark-table, now the work will be completed by June 30
It was first stated by Bharat Biotech on Sunday that its COVID-19 vaccine Covaxin has been found to be effective against corona virus strains found in India and Britain. Referring to the publication published in the Medical Journal Clinical Infectious Disease, the Hyderabad-based vaccine giant said that vaccination with cocaine works against all new variants exposed, including B.1.617 and B.1.1.7. Which were first identified in India and Britain respectively.
Get Business News in Hindi, latest India News in Hindi, and other breaking news on share market, investment scheme and much more on Business Khabar. Like us on Facebook, Follow us on Twitter for latest financial news and share market updates.
.